A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia (FTD) With Granulin Mutation
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs AL 001 (Primary)
- Indications Dementia
- Focus Adverse reactions; First in man
- Acronyms INFRONT
- Sponsors Alector
- 12 Aug 2019 Status changed from recruiting to active, no longer recruiting (in Jul 2019), according to an Alector media release.
- 18 Apr 2019 Planned End Date changed from 30 Sep 2020 to 31 Dec 2019.
- 18 Apr 2019 Planned primary completion date changed from 30 Mar 2020 to 31 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History